Fibrinogen Aalpha312 and Bbeta448 polymorphisms are not related to bleeding during oral vitamin K-antagonist treatment.
Garcia
Andrea A
AA
van der Hoeven
Niels V
NV
Boellaard
Thierry N
TN
van der Heijden
Jeroen F
JF
Groot
Angelique P A
AP
Reitsma
Pieter H
PH
D000074:Acenocoumarol / Q000009:adverse effects; D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects*; D016022:Case-Control Studies; D005340:Fibrinogen / Q000235:genetics*; D005838:Genotype; D006470:Hemorrhage / Q000139:chemically induced* / Q000235:genetics; D006801:Humans; D009426:Netherlands; D016017:Odds Ratio; D010644:Phenprocoumon / Q000009:adverse effects; D020641:Polymorphism, Single Nucleotide; D018570:Risk Assessment; D012307:Risk Factors; D014812:Vitamin K / Q000037:antagonists & inhibitors*
D000925:Anticoagulants; C115499:BBeta fibrinogen; C464794:fibrinogen Aalpha; D014812:Vitamin K; D005340:Fibrinogen; D000074:Acenocoumarol; D010644:Phenprocoumon